9-cis-retinoic acid

9-cis-retinoic acid

AIDS A retinoid that may have some efficacy in topical management of KS Adverse effects Skin irritation, photosensitivity. See AIDSALRT 1057.
Mentioned in ?
References in periodicals archive ?
Combination treatment with 1alpha,25-dihydroxyvitamin D3 and 9-cis-retinoic acid directly inhibits human telomerase reverse transcriptase transcription in prostate cancer cells.
Bollag and Ott had originally shown the effectiveness of 9-cis-retinoic acid as a treatment [1], and results of an extensive trial were published in 2004 [2].
All-trans retinoic acid (RA) and 9-cis-retinoic acid (9cRA) are activators of Retinoic Acid Receptors (RARs).
3] receptor (VDR), peroxisome proliferator-activated receptor (PPAR), liver X receptor (LXR), and FXR, in addition to functioning as a receptor for 9-cis-retinoic acid (9CRA) during formation of a homodimer.
Generally, TRs form heterodimers with the 9-cis-retinoic acid receptor and interact with comodulator complexes, thereby repressing or activating transcription.
The RXR-selective retinoids have a biological activity that is different from that of the endogenous retinoid 9-cis-retinoic acid (alitretinoin), the active substance in Panretin(R) gel and capsules.
Agent Phase Target(s) Retinoids Vitamin A 3 Cervix, lung 13-cis-Retinoic acid 2/3 Head and neck, lung, oral cavity 4-HPR 2/3 Bladder, breast, cervix, lung, oral cavity, prostate 9-cis-Retinoic acid 2 Cervix Calcium 2/3 Colon Tamoxifen 2/3 Breast Aromatase inhibitor 2 Breast Finasteride 3 Prostate 2-Difluoromethylomithine 2 Bladder, breast, cervix, esophagus, oral cavity, prostate Aspirin 2/3 Colon, other epithelial cancers (breast, lung) Perillyl alcohol 2 Breast Piroxicam 2 Colon Cox-2 inhibitor 2 Colon Sulindac 2/3 Colon Oltipraz 2 Liver (DNA adducts), breast, lung Dehydroepiandrosterone analog 2 Breast, prostate IuAcetylcysteine 3 Lung Vitamin [D.
1% 9-cis-retinoic acid as the active agent) to placebo when applied topically, and to determine the safety and tolerability of the formulation in this patient group.
The most significant finding in recent years, I think, is the discovery that the retinoid receptor called 'RXR', or the rexinoid receptor, which binds the derivative 9-cis-retinoic acid and has multiple functions acting in concert (as a heterodimer) with a whole range of other hormone-type receptors in the cell.
More precisely, the metabolic perturbation induced by environmental stimuli leads to the activation of a class of proteins belonging to the nuclear receptor superfamily called peroxisome proliferator-activated receptors (PPARs) [17], which, by forming heterodimers with the 9-cis-retinoic acid receptor X (RXR), recognize response elements (RE) of the promoter region of the above-mentioned target genes and, hence, control their expression.
Both Phase III trials are randomized, double-blind, placebo-controlled 12- week studies of topical 9-cis-retinoic acid gel (Panretin(TM)) in the palliative treatment of cutaneous AIDS-related KS.